SecBot SecBot
DEF 14A ·Filed Oct 26, 2026

ZYME

Zymeworks Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed1d 7h ago SEC0001193125-26-431936
Definitive proxy statement
Actionable Insight • Neutral

Monitor the outcome of Proposal 5 (board declassification) which requires a supermajority vote; if passed, it will phase out the staggered board by 2029. The high say-on-pay support (94%) suggests no imminent compensation-related shareholder activism.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Zymeworks Inc. filed its definitive proxy statement for the 2026 annual meeting of stockholders to be held on December 15, 2026. Key proposals include the election of three Class II directors (Brian N. Cherry, Gregory A. Ciongoli, Oleg Nodelman), an advisory vote on executive compensation, approval of the 2026 Employee Stock Purchase Plan (2,000,000 shares), and declassification of the board of directors. The filing is routine with no material financial surprises; the company reported a net loss of $81.1 million for 2025, but the proxy focuses on governance and compensation matters.

Key Facts

  • Annual meeting scheduled for December 15, 2026, held virtually.
  • Three Class II director nominees: Brian N. Cherry, Gregory A. Ciongoli, Oleg Nodelman.
  • Proposal to declassify the board of directors requires 66 2/3% of outstanding shares.
  • 2026 Employee Stock Purchase Plan seeks approval for 2,000,000 shares (approx. 2.84% of outstanding).
  • Last say-on-pay vote received approximately 94% support.
  • CEO Kenneth Galbraith's 2025 total compensation was $6,613,180; Compensation Actually Paid was $17,844,947.
  • Company reported net loss of $81.1 million for 2025, improving from $122.7 million loss in 2024.
  • EcoR1 Capital LLC beneficially owns 32.59% of common stock; Oleg Nodelman is a director nominee.
  • KPMG LLP appointed as auditors; audit fees for 2025 were $896,432.
  • Stock ownership guidelines adopted for directors and executive officers in 2025.

Financial Impact

No material financial impact from the proxy proposals; the 2026 ESPP authorizes up to 2,000,000 shares (2.84% dilution) but replaces an existing plan with similar share count.

dilution

Risk Factors

  • Proposal 5 requires 66 2/3% approval; failure would maintain classified board structure.
  • Director nominee Oleg Nodelman was fined by French regulator AMF for market abuse violations; appeal pending.
  • Company continues to operate at a net loss ($81.1 million in 2025).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEF 14A Filing (Primary)0001193125-26-431936
Document: 0001193125-26-431936-index-headers.html0001193125-26-431936
Document: 0001193125-26-431936-index.html0001193125-26-431936
Document: 0001193125-26-431936.txt0001193125-26-431936
19 reports for ZYME
Performance horizon
70% Hit rate @ T+1 7 of 10 directional calls Went positive at some point 9 of 10 best @ T+60▲ +16.72%Jun 14, 2026
Filters
Rows
Reports for ZYME — sortable, filterable
TypeNow
Oct 26, 2026
1d ago
DEFA14A
NEUTRAL ★ 2/10
$28.23awaiting T+1—$28.85 (+2.20%)
Oct 26, 2026
1d ago
DEF 14A
NEUTRAL ★ 3/10
$28.37awaiting T+1—$28.85 (+1.69%)
Oct 23, 2026
4d ago
8-K
BULLISH ★ 7/10
$28.22 $28.37▲ +0.53%▼ −0.18%$28.85 (+2.23%)
Oct 15, 2026
12d ago
Press Release
NEUTRAL ★ 1/10
$25.75 $25.03▼ −2.80%▼ −1.69%$28.85 (+12.04%)
Oct 9, 2026
18d ago
144
NEUTRAL ★ 2/10
$25.79 $25.33▼ −1.78%▼ −1.72%$28.85 (+11.87%)
Sep 28, 2026
29d ago
Press Release
BULLISH ★ 7/10
$27.12 $27.20▲ +0.29%▲ +0.48%$28.85 (+6.38%)
Sep 23, 2026
4w ago
Press Release
BULLISH ★ 6/10
$26.81 $26.52▼ −1.08%▼ −1.63%$28.85 (+7.61%)
Aug 25, 2026
9w ago
8-K
BULLISH ★ 8/10
$27.47 $29.31▲ +6.68%▲ +6.66%$28.85 (+5.02%)
Jul 16, 2026
14w ago
Press Release
NEUTRAL ★ 1/10
$24.19awaiting T+1—$28.85 (+19.26%)
Jun 29, 2026
17w ago
Press Release
BULLISH ★ 7/10
$24.10 $26.14▲ +8.46%▲ +7.69%$28.85 (+19.71%)
Showing 10 of 19

US Market Status

Market Closed — Opens Thu (10h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026